Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Full Data For Seattle Genetics’ Lymphoma Drug Shine Bright Light On Antibody Drug Conjugates

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Seattle Genetics and partner Takeda are revising their regulatory strategy and will file their antibody drug conjugate SGN-35 in the first quarter of 2011 for both Hodgkin's lymphoma and anaplastic large cell lymphoma, following a positive reception for their pivotal data at the American Society of Hematology annual meeting.

You may also be interested in...

Takeda Caught Surprised By Outcomes For Two Key Products

TOKYO - Takeda Pharmaceuticals' highly positive Phase III data for antibody drug conjugate SGN-35 (brentuximab vedotin) - partnered with Seattle Genetics - is a bright spot for the company after a "complete response" letter to partner Orexigen for obesity drug Contrave (bupropion/naltrexone)

Seattle Genetics Looks Ahead To BLA Filing For Its Antibody Drug Conjugate

Better-than-expected response rates in pivotal Hodgkin lymphoma trial have company and the Street hopeful for an easy regulatory review.

Takeda Partners With Seattle Genetics On Lymphoma Candidate In Pivotal Trials

Days after losing Roche/Genentech as a partner for dacetuzumab, Seattle Genetics signs Takeda as a partner for a late-stage antibody-drug conjugate.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts